Investors/Media

News Releases

October 8, 2020
SAN FRANCISCO--( BUSINESS WIRE )-- Spruce Biosciences, Inc ., a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet need, today announced the pricing of its initial public offering of 6,000,000 shares of
September 9, 2020
- Dr. Rosh Dias appointed Chief Medical Officer - - Dan Spiegelman appointed to Board of Directors - SAN FRANCISCO--( BUSINESS WIRE )-- Spruce Biosciences , a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant